

Clinical Trials Summary for out of hours Important Reference

| | |
|--|--|
| Acronym study title | IMMU-132-13/TROPiCS-04 IRAS Ref: 1003505 |
| Study Details | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer |
| Principal Investigator / Sub-Is | Professor Alison Birtle Alison.birtle@lthtr.nhs.uk 01772 52 4762 <u>Sub-Is:</u> Dr Natalie Charnley Natalie.chnrley@lthtr.nhs.uk Dr Omi Parikh Omi.parikh@lthtr.nhs.uk |
| Research Nurse Team | Amanda Cook 01772 52 4656 Sheila Calvert 01772 52 3921 |
| Drug therapy | Randomised to either: Sacituzumab Govitecan Versus Treatment of Physician's Choice (Our standard of care would probably be weekly paclitaxel) Sacituzumab govitecan is not currently in use but Dave Barber has just written the D&T application form for it so the Trust maybe using it soon (for breast cancer). Protocol is on the network website under breast cancer |
| In the event that a patient calls this hotline for advice | Please treat as per clinical protocols and inform the clinical and research teams. The medical monitor name and contact information: 24-Hour Emergency Contact: PRA Medical Monitor Email: IMD13213@prahs.com +49 621 878 2850 (Direct) |